Tetra Radar · FDA Approvals · Decision date
FILSPARI: FDA decision date
Akebia Therapeutics Inc. (AKBA) · 13 April 2026
Travere® Therapeutics Inc. developed FILSPARI® (sparsentan), a dual endothelin and angiotensin II receptor antagonist, which is under review by the FDA with a PDUFA target action date of April 13, 2026.
Source: 10-K of 26 February 2026
The date has passed; Tetra Radar has not recorded an approval.
Akebia Therapeutics Inc. on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.